Drug intelligence / Profile preview

atezolizumab + docetaxel + nivolumab + pembrolizumab

Development stage: Preclinical
Lead developer: Genentech
Modality: Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
Administration: Intravenous

Overview

This is a combination of four distinct cancer medications: atezolizumab (a PD-L1 inhibitor), docetaxel (a taxane chemotherapy agent), nivolumab and pembrolizumab (both PD-1 inhibitors). While these drugs have been studied in various combinations (such as atezolizumab plus docetaxel), there is no standard regimen that combines all four agents simultaneously. Atezolizumab (Tecentriq) is a monoclonal antibody that targets PD-L1. Docetaxel is a cytotoxic chemotherapy agent. Nivolumab and pembrolizumab are both PD-1 inhibitors that function as immune checkpoint inhibitors.

Targets

TUBB (Tubulin (alpha and beta subunits))PDCD1 (Programmed cell death protein 1 receptor)CD274 (Programmed cell death protein 1 ligand 1)

Beyond the preview

Go deeper on atezolizumab + docetaxel + nivolumab + pembrolizumab.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on atezolizumab + docetaxel + nivolumab + pembrolizumab.

Explore the full profile